Cas 454423-93-9,L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-N-[2-(2-hydroxyethoxy)ethyl]-

454423-93-9

Post Buying Request

Basic information

Product Name: L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-N-[2-(2-hydroxyethoxy)ethyl]-
Synonyms:
CAS NO:454423-93-9
Molecular Formula: C23H37N3O7
Molecular Weight: 467.563
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-N-[2-(2-hydroxyethoxy)ethyl]-(CAS DataBase Reference)
NIST Chemistry Reference: L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-N-[2-(2-hydroxyethoxy)ethyl]-(454423-93-9)
EPA Substance Registry System: L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-N-[2-(2-hydroxyethoxy)ethyl]-(454423-93-9)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 454423-93-9(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

454423-93-9 Suppliers

Recommended suppliers

454423-93-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 454423-93-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,5,4,4,2 and 3 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 454423-93:
(8*4)+(7*5)+(6*4)+(5*4)+(4*2)+(3*3)+(2*9)+(1*3)=149
149 % 10 = 9
So 454423-93-9 is a valid CAS Registry Number.

454423-93-9Upstream product

454423-93-9Downstream Products

454423-93-9Relevant academic research and scientific papers

Design and synthesis of broad-based mono- and bi- cyclic inhibitors of FIV and HIV proteases

Mak, Chi Ching,Brik, Ashraf,Lerner, Danica L.,Elder, John H.,Morris, Garrett M.,Olson, Arthur J.,Wong, Chi-Huey

, p. 2025 - 2040 (2007/10/03)

Based on the substrate transition state and our strategy to tackle the problem of drug resistance, a series of HIV/FIV protease (HIV/FIV PR) monocyclic inhibitors incorporating a 15- or 17-membered macrocycle with an equivalent P3 or P3′ group and a uniqu

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 454423-93-9